New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Introduction Many neonatal deaths are avoidable using existing low-cost evidence-based interventions. This study evaluated ...
We review Bayesian and Bayesian decision theoretic approaches to subgroup analysis and applications to subgroup-based adaptive clinical trial designs. Subgroup analysis refers to inference about ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDIA ® (finerenone) ...
Exelixis, Inc. today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® versus placebo in patients with previously treated advanced neuroendocrine ...
Results presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU 2025) Treatment with UGN-102 resulted in durable complete response (CR) rates across subgroups ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback